Research programme: CNS disorders therapeutics - (now Teva Pharmaceutical Industries)

Drug Profile

Research programme: CNS disorders therapeutics - (now Teva Pharmaceutical Industries)

Alternative Names: CEP-11124; CEP-16233; CEP-16795

Latest Information Update: 27 Oct 2011

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Cephalon
  • Class
  • Mechanism of Action Histamine H3 receptor antagonists; Histamine H3 receptor inverse agonists; Serotonin 6 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued CNS disorders; Cognition disorders; Schizophrenia; Sleep disorders

Most Recent Events

  • 16 Feb 2010 A lead compound from this research programme has entered clinical trials
  • 04 Dec 2008 Preclinical development is ongoing
  • 27 Mar 2007 Preclinical trials in Cognition disorders in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top